In RP2, the canSERV catalogue was further reviewed and streamlined to ensure that relevant information is available for all services in the catalogue. At the end of RP2, the catalogue included 531 cutting-edge services from 167 service providers across Europe (objective 1). The catalogue offers users easy access to detailed information about the services within all 9 service fields and information about the service providers, including direct links to the service providers websites. The catalogue can be queried based on build-in filters and keywords that have been defined together with the canSERV consortium. As presented in RP1, the canSERV set-up the access management process and the workflow in the Common Access Management System (CAMS). In RP2, different functionalities of the Common Access Management System were further improved or newly developed to support all involved partners in the call phase, evaluation phase and service provision phase. The CAMS system is comprised of: (i) the call phase part that supports the user in selecting the services and submitting their applications, (ii) the evaluation phase that supports the TNA managers, TNA coordinators, IRB members, ethics experts and service providers to evaluate the received application based on the defined specifications and steps of the evaluation process, (iii) service provision phase that helps TNA managers and TNA coordinators to follow the service provision progress between users and service providers and it includes the follow up with the users on the return of the data.
In RP2, canSERV launched five calls: three challenge driven calls (Second Challenge Driven Call ”Reaching an Understanding of Cancer” launched 23.04.2024 Third Challenge Driven Call “Revolutionising Cancer Patient Care” launched 28.05.2024 and Fourth Challenge Driven Call “Training the Next Generation of Cancer Researchers” launched 17.09.2024) and two open calls (Third Open Call for Service Provision launched 29.08.2024 and Fourth Open Call for Service Provision launched 15.04.2025).
In total, 226 applications were received by potential users, out of which 82 were approved for service provision.
Within the context of canSERV, the European Molecular Tumour Board Network (EMTBN) continues to have an important role in fostering the translation of discoveries made in cancer research, also through canSERV TNA services, into possible therapeutic options to consider for MTB recommendations. At the end of RP2, we had 263 registered EMTBN members from 39 countries, mostly from Europe but also from non-European countries (objective 4).
